Leading drug manufacturer, Sun Pharmaceutical Industries has announced that it has got marketing authorization from the US Food and Drug administration (USFDA) for the abbreviated new drug application (ANDA) of its generic version of anti-cough drug ‘Benzonatate.’

In a declaration, the company said, “USFDA has granted approval for the abbreviated new drug application (ANDA) to market a generic version of Forest Labs Tessalon, Benzonatate capsules.”

Benzonatate USP capsules are therapeutically the same as Forest Lab’s Tessalon, and are available in the market in two strengths including 100 mg and 200 mg. It is used to relieve cough due to the common cold, bronchitis, pneumonia, or other lung infections.

Having annual sales of about $40 million in the US, the product will reach market shortly, the company said.

The shares, on Wednesday (19 Mar) of the company gained 0.06 at Rs 1,260.45 on the Bombay Stock Exhamge (BSE). The total volume of shares traded stood at 29,364.